ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC
Biotechnology Research
Weston, Florida 911 followers
ILiAD is advancing the next generation pertussis vaccine for the prevention of whooping cough.
About us
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.
- Website
-
http://www.iliadbio.com
External link for ILiAD Biotechnologies, LLC
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Weston, Florida
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Infectious Diseases and Pediatrics
Locations
-
Primary
Get directions
4581 Weston Road
Suite 260
Weston, Florida 33331, US
Employees at ILiAD Biotechnologies, LLC
Updates
-
ILiAD Biotechnologies will be participating in the following investor conferences: · 4th Annual Needham Private Biotech Company Virtual 1x1 Forum, October 8-9, 2024 · Leerink Partners Biopharma Private Company Connect, October 22-23, 2024 ILiAD management will be hosting virtual 1x1 investor meetings during the conferences.
-
The New York Stock Exchange's Healthcare and Life Sciences Capital Markets team celebrated our Fierce 15 Award with a special event on the NYSE Trading Floor. Thank you! NYSE Fierce Biotech
-
-
Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15 https://lnkd.in/eXVdVv4z
-
-
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
businesswire.com